Estimated compound annual growth rates of competing immuno-oncology agents Keytruda and Opdivo have shown trends over the past year.

While both show positive revenue growth over the next seven years, the rate of growth for Bristol Myers Squibb’s Opdivo has been impacted by the positive opinion of the US Food and Drug Administration (FDA) and, with Merck’s Keytruda recent indication expansion, will be more so impacted by Keytruda’s recent novel FDA approval for treatment of patients whose cancers have a specific biomarker.